BRISTOL-MYERS SQUIBB COMPANY Goodwill, Translation and Purchase Accounting Adjustments
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Goodwill, Translation and Purchase Accounting Adjustments of -$14.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Goodwill and Other
us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY goodwill, translation and purchase accounting adjustments for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY goodwill, translation and purchase accounting adjustments for the quarter ending 2026-03-31 was -$14.00M, a 177.78% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY goodwill, translation and purchase accounting adjustments for the quarter ending 2025-12-31 was $9.00M.
- BRISTOL-MYERS SQUIBB COMPANY goodwill, translation and purchase accounting adjustments for the quarter ending 2025-09-30 was -$30.00M, a 257.89% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY goodwill, translation and purchase accounting adjustments for fiscal 2025 was $36.00M.
- BRISTOL-MYERS SQUIBB COMPANY goodwill, translation and purchase accounting adjustments for fiscal 2024 was -$30.00M, a 250.00% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY goodwill, translation and purchase accounting adjustments for fiscal 2023 was $20.00M.
- BRISTOL-MYERS SQUIBB COMPANY goodwill, translation and purchase accounting adjustments for fiscal 2022 was -$48.00M.
| Period end | Goodwill, Translation and Purchase Accounting Adjustments 3 month | Goodwill, Translation and Purchase Accounting Adjustments 6 month | Goodwill, Translation and Purchase Accounting Adjustments 9 month | Goodwill, Translation and Purchase Accounting Adjustments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$14.00M 10-Q · filed 2026-07-30 | -$5.00M derived: sum of 3 quarters · filed 2026-07-30 | -$35.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$14.00M 10-Q · filed 2026-04-30 | -$5.00M derived: sum of 2 quarters · filed 2026-04-30 | -$35.00M derived: sum of 3 quarters · filed 2026-04-30 | $4.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$21.00M derived: sum of 2 quarters · filed 2026-02-11 | $18.00M derived: sum of 3 quarters · filed 2026-02-11 | $36.00M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$30.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $9.00M derived: sum of 2 quarters · filed 2025-10-30 | $27.00M 10-Q · filed 2025-10-30 | -$5.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | $39.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $57.00M 10-Q · filed 2025-07-31 | $25.00M derived: sum of 3 quarters · filed 2026-02-11 | $44.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | $18.00M 10-Q · filed 2025-04-24 | -$14.00M derived: sum of 2 quarters · filed 2026-02-11 | $5.00M derived: sum of 3 quarters · filed 2026-02-11 | -$1.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | -$32.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$13.00M derived: sum of 2 quarters · filed 2026-02-11 | -$19.00M derived: sum of 3 quarters · filed 2026-02-11 | -$30.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $13.00M derived: sum of 2 quarters · filed 2024-10-31 | $2.00M 10-Q · filed 2024-10-31 | $24.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2024-06-30 | -$6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | -$17.00M 10-Q · filed 2024-07-26 | $5.00M derived: sum of 3 quarters · filed 2025-02-12 | -$11.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2024-03-31 | -$11.00M 10-Q · filed 2024-04-25 | $11.00M derived: sum of 2 quarters · filed 2025-02-12 | -$5.00M derived: sum of 3 quarters · filed 2025-02-12 | -$4.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $6.00M derived: sum of 2 quarters · filed 2025-02-12 | $7.00M derived: sum of 3 quarters · filed 2025-02-12 | $20.00M 10-K · filed 2025-02-12 |
| 2023-09-30 | -$16.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$15.00M derived: sum of 2 quarters · filed 2023-10-26 | -$2.00M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | $14.00M 10-Q · filed 2023-07-27 | ||
| 2023-03-31 | $13.00M 10-Q · filed 2023-04-27 | |||
| 2022-12-31 | -$48.00M 10-K · filed 2024-02-13 | |||
| 2021-12-31 | -$45.00M 10-K · filed 2023-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |